



## Multidrug Resistance in ESKAPE Bacteria and Pathogens

Guest Editor:

### Dr. Véronique Fontaine

Research in Drug Development,  
Faculté de Pharmacie, Université  
libre de Bruxelles (ULB), 1050  
Brussels, Belgium

Deadline for manuscript  
submissions:

**closed (31 August 2023)**

### Message from the Guest Editor

It is well-established that the spread of microorganisms, especially in hospital, of antimicrobial-resistant ESKAPE bacteria and other multi-drug-resistant microorganisms, such as *Mycobacterium tuberculosis*, is alarming. Surveillance and prophylactic measures to restrain the threat of these infections require global understanding of all factors influencing drug tolerance, microorganism persistence and drug resistance development in order to eventually develop the best adapted antimicrobial stewardship or to develop new efficient antimicrobial drug regimens. However, the questions remain: What can we learn from the adaptation of one type of bacteria? Could similar events take place with other microorganisms? Should we assess the fitness cost of drug resistance or tolerance when developing new drug regimens or new antibiotics? It may also be necessary to explore the existing public–private partnerships for drug discovery and development in TB control. We hope that this Special Issue will provide you with new opportunities to present your results. This Issue aims to expand our understanding of antimicrobial bacteria mechanisms and possible means to target them.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)